Articles

KeyCorp to book $700 million loss on sale of securities

The transaction marks an example of efforts by financial firms to reposition their balance sheets with higher-yielding assets as interest rates have risen.

Elon Musk’s SpaceX targets Tuesday for historic Polaris Dawn launch

Elon Musk’s SpaceX is targeting Tuesday for the launch of the historic Polaris Dawn mission but warned that weather conditions are only 40% favorable for the launch, which has already been delayed once.

Squarespace’s stock climbs after buyout bid boosted to $7.2 billion

Squarespace’s stock climbed toward a three-year high in premarket trades Monday, after private-equity firm Permira raised its buyout bid for the online brand-building platform.

MBX Biosciences sets IPO terms with plans to raise up to $136 million

MBX joins the IPO pipeline just days after two other biotechs set terms for their planned deals.

Another iPhone? Boring. Apple must be revolutionary again to save its stock

CEO Tim Cook has been an admirable leader for Apple, but he’s no Steve Jobs.

This chart warning of Europe’s tech failings also may be alarming to the U.S.

Former European Central Bank President and Italian prime minister Mario Draghi on Monday laid out the case for a massive series of investments to boost the region’s stagnant economy.

First American Financial discloses $342 million loss on the sale of bonds

First American Financial Corp. became the latest financial services firm to reveal the pain from holdings of bonds that soured in value.

Palantir, Dell shares rise on S&P 500 nods — and here’s what might come next

After the index change takes hold, “large-cap funds that are benchmarked against the S&P 500 will be forced to look at” Dell, one analyst says.

Can you afford to have a baby? It may cost more than you expect.

With estimates for first-year baby expenses ranging from $15,000 to many thousands more, how can you tell when you’re financially ready to have a child?

Terns Pharmaceuticals’ stock soars 30% after biotech posts positive results in trial of weight-loss drug in pill form

Terns plans to move to a Phase 2 trial for its TERN-601 small-molecule GLP-1 receptor agonist and will submit the latest data to a coming scientific conference.

Nvidia’s sin against Wall Street was that its earnings weren’t even better. Here’s why no one should have been surprised.

Investors are unrealistic about the tech giant’s future growth rate.

Bond yields rise after last week’s slump

Bond yields rose on Monday, part of a broader reversal of trends in financial markets, after last week’s selloff in the stock market.
1 438 439 440 441 442 1,957